Use of at least one glycoinhibitor substance
OwnerJari Natunen, Halina Miller-Podraza +3inventors
InventorsJari Natunen, Halina Miller-Podraza, Susann Teneberg, Jonas Angstrom, Karl-Anders Karlsson
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of a glycosidase inhibitor for the manufacture of a medicament for the treatment of a disease, wherein glycosidase enzymes hydrolyze glycoconjugates of a patient to reveal neutral glycan receptors of an pathogenic agent, and wherein the revealed neutral glycan receptor comprise a oligosaccharide sequence.
Claims66
Use of at least one glycoinhibitor monosaccharide substance comprising a pyranose formed ring structure selected from the group consisting of GlcNAcβ, GalNAcβ, Galβ, Galα, GalNAcα, Fucα, Manα, and Neu5Acα, wherein said monosaccharide substance is linked to a aglycon, for the manufacture of a medicament for the treatment of an infectious disease.
The use according to any one of previous claims, wherein the glycoinhibitor monosaccharide substance is glycosically N-, S-, or C-linked.
The use according to any one of the preceding claims, wherein at least two different glycoinhibitors are used.
Use of Oseltamivir, Zanamivir, or RWJ-270201 as glycoinhibitor substance for the manufacture of a medicament for the treatment of a secondary bacterial infectious disease associated with influenza.
A substance inhibiting glycosidase enzymes, comprising a glycoinhibitor substance comprising a pyranose formed ring structure selected from the group consisting of:
- GlcNAcβ, GalNAcβ, Galβ, Galα, GalNAcα, Fucα, Manα, and Neu5Acα.
Use of a glycosidase inhibitor for the manufacture of a medicament for the treatment of a disease, wherein glycosidase enzymes hydrolyze glycoconjugates of a patient to reveal neutral glycan receptors of a pathogenic agent, and wherein the revealed neutral glycan receptor comprise an oligosaccharide sequence according to the following formula
- [Galβy]p[Hex(NAc)rα/βz]sGalβ4Glc(NAc)u (I)
- wherein p, r, s, and u are each independently 0 or 1, and y is either linkage position 3 or 4, and z is either linkage position 3 or 4, and Hex is either Gal or Glc, so that when p is 1 and y=3, then Hex is Galβ or Glcβ and r=l, or p is 1 and y=4 then Hex is Glcβ and r=1, when p is 0 and z is 4, then Hex is Galβ and r is 1 or Hex is Galα and r is 0
- and wherein the pathogenic agent is fungus, virus, toxin, or bacterium.
Dependencies are inferred from the claim text.